Overview

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects

Status:
Completed
Trial end date:
2011-10-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is investigate the pharmacokinetics, safety and tolerability of single subcutaneous administration of GSK2402968 in non-ambulant boys with Duchenne muscular dystrophy
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline